Summary
Edwards Lifesciences Corporation reported solid revenue growth in the first quarter of 2024, with net sales increasing by 9.5% to $1.6 billion compared to the prior year. This growth was primarily driven by strong performance in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines. The company also incurred significant separation costs related to the planned spin-off of its Critical Care product group, impacting net income. Operationally, the company continues to invest in research and development, essential for its long-term growth strategy in structural heart disease and related therapies. While the company generated positive operating income, the reported net cash used in operating activities was negative, largely due to a substantial tax deposit made related to a contested tax matter. Investors should monitor the progress of the Critical Care spin-off and the resolution of ongoing tax disputes, which could have future financial implications.
Financial Highlights
50 data points| Revenue | $1.33B |
| Cost of Revenue | $286.90M |
| Gross Profit | $1.04B |
| R&D Expenses | $256.70M |
| SG&A Expenses | $428.40M |
| Operating Income | $349.00M |
| Net Income | $351.00M |
| EPS (Basic) | $0.58 |
| EPS (Diluted) | $0.58 |
| Shares Outstanding (Basic) | 601.60M |
| Shares Outstanding (Diluted) | 604.10M |
Key Highlights
- 1Net sales increased by 9.5% to $1.6 billion in Q1 2024 compared to Q1 2023, primarily driven by TAVR and TMTT product sales.
- 2Transcatheter Mitral and Tricuspid Therapies (TMTT) saw a significant 75.2% increase in net sales, highlighting growth in this emerging area.
- 3The company incurred $41.3 million in separation costs related to the planned spin-off of its Critical Care product group.
- 4Diluted Earnings Per Share (EPS) was $0.58, a slight increase from $0.56 in the prior year period.
- 5Net cash used in operating activities was $(53.5) million, significantly impacted by a $305 million tax deposit for contested tax liabilities.
- 6The company ended the quarter with $1.22 billion in cash and cash equivalents, indicating a healthy liquidity position.
- 7The company announced the completion of patient treatment in its PROGRESS pivotal trial for moderate aortic stenosis and received CE Mark approval for its Edwards SAPIEN 3 Ultra RESILIA valve in Europe.